TY - JOUR A2 - Grossberg, George T. AU - Oxford, Alexandra E. AU - Stewart, Erica S. AU - Rohn, Troy T. PY - 2020 DA - 2020/04/01 TI - Clinical Trials in Alzheimer’s Disease: A Hurdle in the Path of Remedy SP - 5380346 VL - 2020 AB - Human clinical trials seek to ameliorate the disease states and symptomatic progression of illnesses that, as of yet, are largely untreatable according to clinical standards. Ideally, clinical trials test “disease-modifying drugs,” i.e., therapeutic agents that specifically modify pathological features or molecular bases of the disease and would presumably have a large impact on disease progression. In the case of Alzheimer’s disease (AD), however, this approach appears to have stalled progress in the successful development of clinically useful therapies. For the last 25 years, clinical trials involving AD have centered on beta-amyloid (A β）和甲 βAD进展和病理的假说。根据这个假设，AD进展开始以下A的积累 β肽，导致最终的突触丧失和神经细胞死亡：AD的真正压倒一切的病理特征。从A引起的临床试验 β该途径中的假设目标因果的步骤，以减少A的形成 β或提高清关，虽然代理这个目标已经成功，他们仍然在抢救认知功能或减缓认知能力下降不成功。如在治疗方案的开发，例如，还使用资源AD的该目标甲 β，其前体，或它的产品应该重新评估。这次审查的目的是给如何人体临床试验的概述在美国被进行，以评估近期涉及AD试验失败的结果，其中大部分是基于A β假设。基于这些目前的调查结果，因此建议降低相关联的 β是一个未经证实的策略，它可能是时间对其他目标重新调整对本病包括τ的病理形式的治疗。SN - 2090-8024 UR - https://doi.org/10.1155/2020/5380346 DO - 10.1155 /五百三十八万○三百四十六分之二千○二十○JF - 国际期刊阿尔茨海默氏病的PB - Hindawi出版KW - ER -